Literature DB >> 31626136

Risk factors for the development of hyperuricemia: A STROBE-compliant cross-sectional and longitudinal study.

Qun Ni1, Xiaomin Lu, Congcong Chen, Huaqing Du, Renbing Zhang.   

Abstract

Hyperuricemia has received increasing attention as a major public health problem. This study aims to investigate the risk factors for hyperuricemia and to explore the relationship between changes in biochemical variables and incident hyperuricemia.A cross-sectional and subsequently prospective study was performed among adults who took their health checkups at Zhejiang University Hospital. The participants who were free of hyperuricemia at baseline received annual follow-up examinations during a 6-year period. Cox proportional hazards regression analyses were conducted to calculate the risks for incident hyperuricemia.Of the 9238 participants enrolled, 1704 (18.4%) were diagnosed as hyperuricemia. During 21,757 person-years of follow-up, 1492 incident hyperuricemia cases were identified. The incidence of hyperuricemia was 68.58 cases per 1000 person-year of follow-up in the overall participants. The prevalence and the incidence of hyperuricemia increased greatly in female older than 50 years. High levels of BMI, SBP, FPG, TG, LDL-C, ALT, BUN, and creatinine increased the risk of hyperuricemia. Suffering fatty liver also increased the risk of hyperuricemia. Subjects with increasing DBP, TG, BUN, creatinine, or decreasing HDL-C were more likely to incident hyperuricemia.This study revealed that the change of diastolic blood pressure (DBP), serum triglycerides (TG), blood urea nitrogen (BUN), creatinine, and high-density lipoprotein cholesterol (HDL-C) level were independently associated with incident hyperuricemia.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31626136      PMCID: PMC6824661          DOI: 10.1097/MD.0000000000017597

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


Introduction

Uric acid is the final enzymatic product of purine metabolism and it has the ability to scavenge oxygen radicals and protect the erythrocyte membrane from lipid oxidation.[ However, elevated serum uric acid (hyperuricemia) is associated with significantly increased risk for gout, cardiovascular disease, chronic kidney disease (CKD), and type 2 diabetes mellitus. Hyperuricemia has received increasing attention as a major public health problem in China because of its high prevalence and the associated increases in the risk of gout, hypertension, cardiovascular disease and CKD.[ What is more, hyperuricemia also plays an important role in metabolic related diseases, such as metabolic syndrome, diabetes and non-alcoholic fatty liver disease (NAFLD).[ The prevalence of hyperuricemia varies across different populations and different areas. In the first decades of 21st century, an epidemiological survey estimates approximately 43.3 million US adults (21.4%) met criteria for hyperuricemia.[ A cross-sectional reported that the prevalence of hyperuricemia among Chinese adults was 8.4%,[ and a meta-analysis indicated the pooled prevalence of hyperuricemia was 13.3% in China.[ To better understanding of which individuals are at risk of developing hyperuricemia is crucial. Nowadays, more and more research focuses on the risk factors of hyperuricemia. Peng et al found that, low-density lipoprotein cholesterol (LDL-C), triglycerides (TGs), total cholesterol, apolipoprotein-B levels, ratio of TGs to high-density lipoprotein cholesterol (HDL-C) were strongly associated with serum uric acid levels, whereas serum HDL-C levels were significantly inversely associated.[ A study from US reported that individuals with uncontrolled blood pressure and additional cardiovascular disease risk factors demonstrated a 4-fold or greater prevalence of hyperuricemia.[ Another study also showed that higher blood hematocrit was independently associated with the incidence of hyperuricemia.[ However, most of these studies were cross-sectional in nature and thus could not address the cause-effect relationship between the variables and hyperuricemia. Moreover, some prospective studies related to hyperuricemia did not assess the relationship between the changes in variables and incident hyperuricemia. In this study, we conducted a cross-sectional and prospective study in a Chinese population to find the risk factors for hyperuricemia and to explore the relationship between changes in variables and incident hyperuricemia.

Methods

Study population

We conducted a cross-sectional and subsequently prospective study among adults who took their health checkups at Zhejiang University Hospital. At baseline, all the participants who took their annual health checkups in 2011 were screened for enrollment. Those with missing data on serum uric acid or other variables, or those with a history of malignancy were excluded. A total of 9238 participants (5258 men and 3980 women) were qualified for the cross-sectional study. The participants who were free of hyperuricemia at baseline were followed up annually.

Baseline evaluations

Baseline examinations were performed according to previously described procedures. We collected the standing height, body weight, and blood pressure for all participants. Height and weight were measured while participants were wearing light clothing without shoes. Body mass index (BMI) (kg/m2) is calculated as the body weight (kg) divided by the standing height (m) squared. Blood pressure was measured using a standard protocol. Fasting serum samples were obtained for the analysis of biochemical values. The values were measured by an Hitachi 7180 auto-analyzer (Hitachi, Tokyo, Japan) using standard methods. Hyperuricemia was defined as serum uric acid levels >420 μmol/L in men and >360 μmol/L in women, and/or taking medication for hyperuricemia. Fatty liver was diagnosed by abdominal ultrasound examination. Trained ultrasonographists performed abdominal ultrasound examinations with a Sonoline G60S ultrasound system with a 3.5-MHz probe (Siemens, Erlangen, Germany). The ultrasonographists were blinded to the study design and the clinical data. The criteria for ultrasonic diagnosis of fatty liver were based on those suggested by the Chinese Liver Disease Association.

Follow-up evaluations

To identify incident cases of hyperuricemia during the follow-up period, the subjects who were free of hyperuricemia at baseline received annual follow-up examinations during a 6-year period. The method used for the measurement of serum uric acid and the definition of hyperuricemia was the same as that used at baseline. Incident hyperuricemia was identified if serum uric acid levels higher than the threshold (>420 μmol/L in men and >360 μmol/L in women) were detected at any of the follow-up examinations. The follow-up time was calculated as the difference between baseline and the examination when incident hypertension was first identified. For participants who did not develop hyperuricemia, the follow-up time was censored at the last known follow-up examination.

Ethics

All participants were verbally informed about the study's aim and procedures, and voluntarily consented to participate. The subject information was anonymized at collection and prior to analysis. All methods were performed in accordance with the approved guidelines. The study gained approval of the Ethics Committee of Zhejiang University Hospital.

Statistical analysis

The statistical analyses were performed using SPSS 18.0 (SPSS, Chicago, IL). Continuous variables were presented as medians and interquartile range. They were compared by Student's t test or Mann–Whitney U test, one-way ANOVA with post hoc Tukey's test, or Kruskal–Wallis test with Bonferroni correction as appropriate. Categorical variables were compared using the χ2 test. Cochran–Armitage trend test was used to show the trend of the prevalence. A stepwise logistic regression analysis was performed to examine the relationship between hyperuricemia and anthropometric or biochemical variables (probability to enter = .05 and probability to remove = .10). Cox proportional hazards regression analyses were applied to calculate the risks for incident hyperuricemia. Backward stepwise regression was used in multivariate Cox proportional hazards regression analyses (probability to enter = .05 and probability to remove = .10). A P value <.05 (two-tailed) was considered to be statistically significant.

Results

Baseline characteristics

A total of 9238 participants with a median age of 49.0 were included in this study, 5258 were male and 3980 were female. Of the 9238 participants enrolled, 1704 (18.4%) were diagnosed as hyperuricemia. The characteristics of participants according to baseline hyperuricemia status are presented in Table 1. The participants with hyperuricemia had greater BMI, higher systolic and diastolic blood pressure, fasting plasma glucose (FPG), and worse lipid profiles compared with those without hyperuricemia. Moreover, there were significant differences in alanine aminotransferase (ALT), blood urea nitrogen (BUN), creatinine, total bilirubin between the two groups.
Table 1

Characteristics of participants according to their baseline hyperuricemia status.

Characteristics of participants according to their baseline hyperuricemia status. The prevalence of hyperuricemia was almost the same in different age groups in male, while the prevalence of hyperuricemia increased in female older than 50 year (Fig. 1). We analyzed the risk factors of hyperuricemia by stepwise logistic regression analysis. The multivariable model showed that BMI, SBP, FPG, TGs, LDL-C, ALT, BUN, and creatinine were associated with risk for hyperuricemia (Table 2). Whether suffering from fatty liver were also associated with risk for hyperuricemia.
Figure 1

The prevlance of hyperuricemia according to the gender and age.

Table 2

Stepwise logistic regression analysis of hyperuricemia with anthropometric and biochemical variables.

The prevlance of hyperuricemia according to the gender and age. Stepwise logistic regression analysis of hyperuricemia with anthropometric and biochemical variables.

Follow-up outcomes

A total of 7534 participants (3986 male and 3548 female) without hyperuricemia were enrolled at baseline of the 6-year follow up. During 21,757 person-years of follow-up, 1492 incident hyperuricemia cases were identified. The incidence of hyperuricemia was 68.58 cases per 1000 person-year of follow-up in the overall participants. The participants who developed hyperuricemia had higher baseline than those who did not in terms of gender, blood pressure, BMI, FPG, TG, total cholesterol (TC), LDL-C, ALT, BUN, creatinine, and lower baseline levels of HDL-C (Table 3).
Table 3

Comparison of baseline characteristics of participates according to follow-up outcomes.

Comparison of baseline characteristics of participates according to follow-up outcomes. The incidence of hyperuricemia decreased in male older than 60 years, while the incidence of hyperuricemia in female increased with age (Fig. 2). Cox proportional hazards regression analyses were applied to explore the risk factors of incident hyperuricemia. The multivariable model showed that gender, BMI, systolic blood pressure (SBP), TG, TC, LDL-C, BUN, and creatinine were associated with risk factors of incident hyperuricemia. Besides, participates who had fatty liver at baseline were more likely to develop hyperuricemia (Table 4).
Figure 2

The incidence of hyperuricemia according the gender and age.

Table 4

Univariate and multivariate Cox proportional hazards regression analyses for the population.

The incidence of hyperuricemia according the gender and age. Univariate and multivariate Cox proportional hazards regression analyses for the population.

Changes of variables and risk for incident hyperuricemia

We next assessed the changes of the variables mentioned above and the risk for incident hyperuricemia. By univariate analysis, incident hyperuricemia was associated with increasing diastolic blood pressure (DBP), TG, ALT, BUN, creatinine, and decreasing SBP and HDL-C. By multivariate analysis, increasing DBP, TG, BUN, creatinine, and decreasing HDL-C remained as independent factors associated with incident hyperuricemia (Table 5).
Table 5

Factors associated with incident hyperuricemia.

Factors associated with incident hyperuricemia.

Discussion

In this study, we confirmed that gender, BMI, SBP, TG, TC, LDL-C, BUN, and creatinine were associated with risk factors of incident hyperuricemia. Moreover, we provided evidence that increasing DBP, TG, BUN, creatinine, and decreasing HDL-C level also independently associated with incident hyperuricemia. Previous meta-analysis showed that the prevalence of hyperuricemia in China was about 13.3%.[ Zhang et al also reported that the incidence of hyperuricemia was 22.4 per 1000 in a 3-year prospective study.[ Besides, a long-term research found that the incidence of hyperuricemia was 43.6 per 1000 person-year.[ In this cross-sectional study, we observed that the prevalence of hyperuricemia in this population was 18.4%, and in the prospective study, the incidence of hyperuricemia was 68.58 cases per 1000 person-year. Epidemiological surveys showed that hyperuricemia is quite prevalent in areas with high gross domestic product levels in China.[ The differences in prevalence and incidence of hyperuricemia may be attributed to the rapidly developing economy in Hangzhou. It is worth noting that with the acceleration of China's economic development, the prevalence and incidence of hyperuricemia may increase further. In this study, we observed that the prevalence and the incidence of hyperuricemia increased greatly in female more than 50 years old. This phenomenon was also found in other studies.[ This is primarily attributable to sex hormone effects on renal urate transport. It has been reported that estrogen plays a role in renal clearance, secretion and reabsorption thus affect SUA levels.[ Young adult women have lower serum urate levels than young adult men, but the onset of menopause is associated with increased serum urate levels.[ Several cross-sectional studies have showed that lipid profiles are closely related to hyperuricemia.[ Some drugs used to treat dyslipidemia like fenofibrate were effective in reducing serum concentration of uric acid.[ Our study suggested that the changes in lipid profiles were independent factors associated with incident hyperuricemia, this results further demonstrated that dyslipidemia could cause hyperuricemia, especially TG and HDL-C. Our study is consistent with previous studies that NAFLD was strongly associated with subsequent development of hyperuricemia.[ Some prospective studies also indicated that serum uric acid levels independently predicted increased risk for incident NAFLD.[ These evidences showed that NAFLD and hyperuricemia could cause and worsen each other and result in a more deteriorated metabolic status. Treatment of asymptomatic hyperuricemia has been found to improve health outcomes in patients. It is reported that treating asymptomatic hyperuricemia is s most effective in preventing vascular events in a serum urate above 7.0 mg/dL in men and 5.0 mg/dL in women.[ Our findings may help guide clinical decision-making to help identify which patients are at highest risk of developing hyperuricemia based on patient characteristics. Several limitations were acknowledged in this study. First, dietary and lifestyle information was not collected, although dietary intake could be a cofactor associated with hyperuricemia. Some studies have showed that fructose-enriched food and drink could increase serum UA levels.[ While high tea intake and consuming midnight snack rarely are significantly related to decreased risk of hyperuricemia.[ Meanwhile, we did not assess the changes in variables and disease outcomes in individuals after treatment for hyperuricemia, future research should establish the clinical effectiveness of predicting and treating incident hyperuricemia to prevent the onset of adverse outcomes. In conclusion, our study found that the change of DBP, serum TG, BUN, creatinine, and HDL-C level were independently associated with incident hyperuricemia. This finding may help identify which patients are at highest risk of developing hyperuricemia. Clinicians should pay attention to the changes of these indicators to reduce the incidence of hyperuricemia.

Author contributions

Conceptualization: Renbing Zhang. Data curation: Qun Ni. Formal analysis: Xiaomin Lu. Methodology: Congcong Chen. Project administration: Huaqing Du. Software: Huaqing Du. Validation: Congcong Chen. Visualization: Xiaomin Lu. Writing – original draft: Qun Ni. Writing – review & editing: Renbing Zhang.
  27 in total

1.  Prevalence of hyperuricemia among Chinese adults: a national cross-sectional survey using multistage, stratified sampling.

Authors:  Hong Liu; Xiao-Min Zhang; Yan-Li Wang; Bi-Cheng Liu
Journal:  J Nephrol       Date:  2014-04-01       Impact factor: 3.902

Review 2.  Regulation of uric acid metabolism and excretion.

Authors:  Jessica Maiuolo; Francesca Oppedisano; Santo Gratteri; Carolina Muscoli; Vincenzo Mollace
Journal:  Int J Cardiol       Date:  2015-08-14       Impact factor: 4.164

3.  High serum ferritin levels increase the risk of hyperuricemia: a cross-sectional and longitudinal study.

Authors:  Ya-nan Zhang; Chengfu Xu; Lei Xu; Chaohui Yu; Min Miao; Jianhong Xie; Youming Li
Journal:  Ann Nutr Metab       Date:  2014-03-13       Impact factor: 3.374

Review 4.  Hyperuricemia, gout, and cardiovascular disease: an update.

Authors:  Aryeh M Abeles
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

5.  Factors contributing to increased serum urate in postmenopausal Japanese females.

Authors:  M Koga; H Saito; M Mukai; S Kasayama; T Yamamoto
Journal:  Climacteric       Date:  2009-04       Impact factor: 3.005

6.  Risk factors for incident hyperuricemia during mid-adulthood in African American and white men and women enrolled in the ARIC cohort study.

Authors:  Mara A McAdams-DeMarco; Andrew Law; Janet W Maynard; Josef Coresh; Alan N Baer
Journal:  BMC Musculoskelet Disord       Date:  2013-12-11       Impact factor: 2.362

Review 7.  Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies.

Authors:  Ji Wang; Tianqiang Qin; Jianrong Chen; Yulin Li; Ling Wang; He Huang; Jing Li
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

8.  Higher blood hematocrit predicts hyperuricemia: a prospective study of 62,897 person-years of follow-up.

Authors:  Chao Zeng; Jie Wei; Tuo Yang; Hui Li; Wen-Feng Xiao; Wei Luo; Shu-Guang Gao; Yu-Sheng Li; Yi-Lin Xiong; Guang-Hua Lei
Journal:  Sci Rep       Date:  2015-09-04       Impact factor: 4.379

9.  Associations of non-high density lipoprotein cholesterol and traditional blood lipid profiles with hyperuricemia among middle-aged and elderly Chinese people: a community-based cross-sectional study.

Authors:  Juan Xu; Hao Peng; Qinghua Ma; Xiaohua Zhou; Wenxin Xu; Liang Huang; Jiarong Hu; Yonghong Zhang
Journal:  Lipids Health Dis       Date:  2014-07-23       Impact factor: 3.876

Review 10.  Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis.

Authors:  Rui Liu; Cheng Han; Di Wu; Xinghai Xia; Jianqiu Gu; Haixia Guan; Zhongyan Shan; Weiping Teng
Journal:  Biomed Res Int       Date:  2015-11-10       Impact factor: 3.411

View more
  13 in total

1.  Associaton of Retinol Binding Protein 4 (RBP4) Levels With Hyperuricemia: A Cross-Sectional Study in a Chinese Population.

Authors:  Guo-Bao Hong; Xiao-Fei Shao; Jia-Min Li; Qin Zhou; Xiao-Su Ke; Pei-Chun Gao; Xiao-Lin Li; Jing Ning; Hai-Shan Chen; Hua Xiao; Chong-Xiang Xiong; Hequn Zou
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

2.  Fatty liver index for hyperuricemia diagnosis: a community-based cohort study.

Authors:  Jianchang Qu; Jingtao Dou; Anping Wang; Yingshu Liu; Lu Lin; Kang Chen; Li Zang; Yiming Mu
Journal:  BMC Endocr Disord       Date:  2022-04-30       Impact factor: 3.263

3.  Prevalence and Risk Factors of Hyperuricemia in Patients with Chronic Kidney Disease and Non-Alcoholic Fatty Liver.

Authors:  Sima Golmohammadi; Marjan Tavasoli; Nadia Asadi
Journal:  Clin Exp Gastroenterol       Date:  2020-08-20

4.  Study on the Risk Factors for Hyperuricaemia and Related Vascular Complications in Patients with Type 2 Diabetes Mellitus.

Authors:  Rong Shi; Zheyun Niu; Birong Wu; Fan Hu
Journal:  Risk Manag Healthc Policy       Date:  2020-09-21

5.  Incidence and Risk Factors of Hyperuricemia among 2.5 Million Chinese Adults during the Years 2017-2018.

Authors:  Ruiqi Shan; Yi Ning; Yuan Ma; Xiang Gao; Zechen Zhou; Cheng Jin; Jing Wu; Jun Lv; Liming Li
Journal:  Int J Environ Res Public Health       Date:  2021-02-28       Impact factor: 3.390

6.  Reduced renal function may explain the higher prevalence of hyperuricemia in older people.

Authors:  Yutang Wang; Wanlin Zhang; Tingting Qian; Hui Sun; Qun Xu; Xujuan Hou; Wenqi Hu; Guang Zhang; Grant R Drummond; Christopher G Sobey; Fadi J Charchar; Jonathan Golledge; Guang Yang
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

7.  Risk Predictors of High Uric Acid Levels Among Patients with Type-2 Diabetes.

Authors:  Zobeida Eljaaly; Muhammad Mujammami; Shaik Sarfaraz Nawaz; Mohamed Rafiullah; Khalid Siddiqui
Journal:  Diabetes Metab Syndr Obes       Date:  2021-12-24       Impact factor: 3.168

8.  Establishment of sex difference in circulating uric acid is associated with higher testosterone and lower sex hormone-binding globulin in adolescent boys.

Authors:  Yutang Wang; Fadi J Charchar
Journal:  Sci Rep       Date:  2021-08-30       Impact factor: 4.379

9.  Sex-Specific Differences in the Association of Metabolically Healthy Obesity With Hyperuricemia and a Network Perspective in Analyzing Factors Related to Hyperuricemia.

Authors:  Simiao Tian; Yazhuo Liu; Ao Feng; Shulong Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-06       Impact factor: 5.555

10.  Antihyperuricemic Effect of Dendropanax morbifera Leaf Extract in Rodent Models.

Authors:  Dongho Lee; Jin-Kyoung Kim; Yongjae Han; Kwang Il Park
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-23       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.